...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Saudi Journal of Biological Sciences >Therapeutic effect of autologous bone marrow stem cell mobilization combined with anti-infective therapy on moyamoya disease
【24h】

Therapeutic effect of autologous bone marrow stem cell mobilization combined with anti-infective therapy on moyamoya disease

机译：自体骨髓干细胞动员与抗感染治疗对Moyamoya病的治疗作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective The purpose of this study is to explore the therapeutic effect of autologous bone marrow stem cell (ABMSC) mobilization combined anti-infection therapy on patients with moyamoya disease (MMD), and to provide reference for the clinical treatment of MMD and cerebrovascular disease. Methods 54 adult patients with MMD diagnosed in Henan Provincial People’s Hospital from March 2017 to March 2019 were chosen as research objects. All patients were randomly divided into study group (SG) and control group (CG), with 27 patients in each group. Patients in both groups received conventional drug treatment after diagnosis of MMD, and received dura turnover of brain - temporal muscle - superficial temporal artery application surgery during indirect vascular reconstruction. On the basis of surgical treatment, patients in the SG were given ABMSC mobilization combined with low-dose dexamethasone for anti-inflammatory and anti-infection treatment. ABMSCs were mobilized by recombinant human granulocyte colony stimulating factor (rhG-csF) and recombinant human granulocyte - macrophage colony stimulating factor (rhoM-esF). The therapeutic effects of the patients were evaluated BF, one month after treatment (AF), three months AF, and six months AF. The number of hematopoietic stem cells (HpCs) and inflammatory indicators were compared between the two groups before and 4?weeks AF. Results Firstly, the Barthcl index of patients in the two groups showed a gradual increase trend at the 3rd and 6th months AF, and the ascensional range in the research group was higher than that in the CG (P??0.05). Secondly, at the 3rd and 6th month AF, national institute of heath stroke scale (NIHSS) scores of patients in the CG were lower than those before treatment (BF), and there was an important change in NIHSS scores between the two groups at the same period (P??0.05). Thirdly, after 1?month of treatment and 3?months of treatment, Chinese stroke scale (CSS) scores of patients in both groups decreased obviously compared with those BF, and the SG was lower than the CG, with statistical changes (P??0.05). Fourthly, after 4?weeks of treatment, the hematopoietic stem cell counts in both groups were higher than those BF, and the hematopoietic stem cell counts in the SG were obviously higher than those in the CG (P??0.05). All three inflammatory indicators were improved compared with those BF, and the SG was better than the CG (P??0.05). Conclusion Autogenous bone marrow stem cell mobilization combined with dexamethasone anti-inflammation and anti-infection treatment after revascularization in patients with MMD can accelerate the recovery of nerve function and promote the formation of new blood vessels. At the same time, it can reduce inflammation and improve patients' quality of life, which is worthy of clinical reference.
机译：目的本研究的目的是探讨自体骨髓干细胞（ABMSC）动员组合抗感染治疗对Moyamoya病（MMD）的患者的治疗效果，并为MMD和脑血管病的临床治疗提供参考。方法从2017年3月至2019年3月均诊断河南省人民医院患有MMD的成年患者作为研究对象。将所有患者随机分为研究组（SG）和对照组（CG），每组27例患者。两组患者在诊断MMD后接受常规药物治疗，并在间接血管重建期间接受了脑颞肌肌肤浅表颞型动脉施用手术的Dura周转。在手术治疗的基础上，SG中的患者被赋予ABMSC动员与低剂量地塞米松联合用于抗炎和抗感染治疗。通过重组人粒细胞菌落刺激因子（RHG-CSF）和重组人粒细胞 - 巨噬细胞群刺激因子（RHOM-ESF）调动ABMSCs。患者的治疗效果评估了BF，治疗后一个月（AF），三个月AF和六个月AF。比较两组和4周AF之间的两组之间的造血干细胞（HPC）和炎症指标的数量。结果首先，两组患者的Barthcl指数在第3个月和第6个月的AF中逐渐增加，研究组的上升范围高于CG（P？<β05）。其次，在第三个和第6个月AF，CG中的患者的国家荒地卒中量表（NIHSS）评分低于治疗前（BF）的患者，并且在两组之间的NIHSS分数存在重要变化同期（p？<？0.05）。第三，在1？月份治疗和3个月治疗后，与那些BF相比，两组患者的中风鳞（CSS）评分明显下降，并且SG低于CG，统计变化（P？< ？0.05）。第四，在治疗4周后，两组造血干细胞计数高于那些BF，SG中的造血干细胞计数明显高于CG中的细胞（P？<→0.05）。与那些BF相比，所有三种炎症指标得到改善，SG比CG更好（P？<？0.05）。结论自生骨髓干细胞动员与血管内血管化后的抗炎症和抗感染治疗联合MMD患者的复苏术后，促进新血管的形成。与此同时，它可以减少炎症，提高患者的生活质量，这是值得临床参考。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号